Editorial Comment

The document discussed how prostate volume significantly influenced PSA levels in men with benign prostatic hyperplasia, with PSA levels serving as a good indicator of prostate size. Treatment was typically reserved for those whose quality of life was impacted by symptoms, with therapy selection based on prostate size and PSA levels. For prostates not markedly enlarged (<30 cm3) and PSA <1.5 μg/L, α1-blockers like tamsulosin or alfuzosin were recommended. For larger prostates or PSA >1.5 μg/L, either 5α-reductase inhibitors or α1-blockers were used. Combination therapy, though more effective, was suggested only for high-risk patients (prostate volume >40 cm3 or PSA >4 ng/mL) due to its higher cost.